Analysis of the Composition and Functions of the Microbiome in Diabetic Foot Osteomyelitis Based on 16S rRNA and Metagenome Sequencing Technology

Diabetes. 2020 Nov;69(11):2423-2439. doi: 10.2337/db20-0503. Epub 2020 Aug 14.

Abstract

Metagenome sequencing has not been used in infected bone specimens. This prospective observational study explored the microbiome and its function in patients with diabetic foot osteomyelitis (DFO) and posttraumatic foot osteomyelitis (PFO) based on 16S rRNA sequencing and metagenome sequencing technologies. Spearman analysis was used to explore the correlation between dominant species and clinical indicators of patients with DFO. High-throughput sequencing showed that all the specimens were polymicrobial. The microbial diversity was significantly higher in the DFO group than in the PFO group. Firmicutes, Prevotellaceae, and Prevotella were the most abundant microbes in the DFO group. The most abundant microbes in the PFO group were Proteobacteria, Halomonadaceae, and Halomonas Prevotella denticola, Prevotella jejuni, and Prevotella fusca had positive correlation with the duration of diabetic foot infection (DFI_d). Proteus vulgaris was positively correlated with the infection index, while Bacteroides fragilis was negatively correlated. The microbial functional genes were more abundant in the DFO group than in the PFO group. Metagenome sequencing is feasible for the analysis of the microbiome in infected bone specimens. Gram-negative bacteria and anaerobes are dominant in DFO.

Trial registration: ClinicalTrials.gov NCT04240964.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Diabetic Foot / complications*
  • Female
  • Humans
  • Male
  • Metagenome / genetics*
  • Metagenomics / methods
  • Microbiota / genetics*
  • Middle Aged
  • Osteomyelitis / microbiology*
  • RNA, Bacterial / genetics
  • RNA, Ribosomal, 16S / genetics*
  • Sequence Analysis, RNA / methods

Substances

  • RNA, Bacterial
  • RNA, Ribosomal, 16S

Associated data

  • ClinicalTrials.gov/NCT04240964